CLOV Strangle Strategy
CLOV (Clover Health Investments, Corp.), in the Healthcare sector, (Medical - Healthcare Plans industry), listed on NASDAQ.
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
CLOV (Clover Health Investments, Corp.) trades in the Healthcare sector, specifically Medical - Healthcare Plans, with a market capitalization of approximately $1.84B, a beta of 2.45 versus the broader market, a 52-week range of 1.58-3.92, average daily share volume of 5.8M, a public-listing history dating back to 2020, approximately 570 full-time employees. These structural characteristics shape how CLOV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.45 indicates CLOV has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on CLOV?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CLOV snapshot
As of May 15, 2026, spot at $3.40, ATM IV 61.73%, IV rank 19.54%, expected move 17.70%. The strangle on CLOV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this strangle structure on CLOV specifically: CLOV IV at 61.73% is on the cheap side of its 1-year range, which favors premium-buying structures like a CLOV strangle, with a market-implied 1-standard-deviation move of approximately 17.70% (roughly $0.60 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CLOV expiries trade a higher absolute premium for lower per-day decay. Position sizing on CLOV should anchor to the underlying notional of $3.40 per share and to the trader's directional view on CLOV stock.
CLOV strangle setup
The CLOV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CLOV near $3.40, the first option leg uses a $3.57 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CLOV chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CLOV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.57 | N/A |
| Buy 1 | Put | $3.23 | N/A |
CLOV strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CLOV strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CLOV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CLOV
Strangles on CLOV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CLOV chain.
CLOV thesis for this strangle
The market-implied 1-standard-deviation range for CLOV extends from approximately $2.80 on the downside to $4.00 on the upside. A CLOV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CLOV IV rank near 19.54% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CLOV at 61.73%. As a Healthcare name, CLOV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CLOV-specific events.
CLOV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CLOV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CLOV alongside the broader basket even when CLOV-specific fundamentals are unchanged. Always rebuild the position from current CLOV chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CLOV?
- A strangle on CLOV is the strangle strategy applied to CLOV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CLOV stock trading near $3.40, the strikes shown on this page are snapped to the nearest listed CLOV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CLOV strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CLOV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 61.73%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CLOV strangle?
- The breakeven for the CLOV strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CLOV market-implied 1-standard-deviation expected move is approximately 17.70%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CLOV?
- Strangles on CLOV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CLOV chain.
- How does current CLOV implied volatility affect this strangle?
- CLOV ATM IV is at 61.73% with IV rank near 19.54%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.